J P Morgan Chase & Co set a €125.00 ($148.81) price objective on Bayer (FRA:BAYN) in a research note published on Friday morning. The firm currently has a buy rating on the healthcare company’s stock.

Several other research analysts have also issued reports on BAYN. Sanford C. Bernstein set a €131.00 ($155.95) price target on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, November 29th. Independent Research set a €120.00 ($142.86) price target on shares of Bayer and gave the stock a neutral rating in a research note on Tuesday, November 28th. UBS set a €125.00 ($148.81) price target on shares of Bayer and gave the stock a buy rating in a research note on Monday, November 27th. Barclays set a €105.00 ($125.00) price target on shares of Bayer and gave the stock a sell rating in a research note on Friday, November 17th. Finally, Commerzbank set a €124.00 ($147.62) price target on shares of Bayer and gave the stock a buy rating in a research note on Wednesday, November 15th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of Buy and an average price target of €122.43 ($145.75).

Bayer (FRA:BAYN) opened at €107.40 ($127.86) on Friday. Bayer has a 1-year low of €86.06 ($102.45) and a 1-year high of €123.82 ($147.40).

TRADEMARK VIOLATION WARNING: “Bayer (BAYN) Given a €125.00 Price Target by J P Morgan Chase & Co Analysts” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/05/bayer-bayn-given-a-125-00-price-target-by-j-p-morgan-chase-co-analysts.html.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Stock Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related stocks with our FREE daily email newsletter.